Attitudes towards prescribing cognitive enhancers among primary care physicians in Germany

BMC Family Practice

Volumn 15, Issue 1, 2014, Pages

  Franke, Andreas G ^a,b   Papenburg, Carolin ^a   Schotten, Elena ^a   Reiner, Peter B ^c   Lieb, Klaus ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b Hochschule Neubrandenburg   (Germany)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Cognitive enhancement; Prescription drug(s); Primary care physician(s)

Indexed keywords

NOOTROPIC AGENT;

ADULT; AGED; ARTICLE; ATTITUDE TO HEALTH; CLINICAL PRACTICE; FEMALE; GENERAL PRACTITIONER; GERMANY; HEALTH PERSONNEL ATTITUDE; HUMAN; MALE; MIDDLE AGED; PRESCRIPTION; QUESTIONNAIRE; STANDARD; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ATTITUDE OF HEALTH PERSONNEL; DRUG PRESCRIPTIONS; FEMALE; GERMANY; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MALE; MIDDLE AGED; NOOTROPIC AGENTS; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS, PRIMARY CARE; QUESTIONNAIRES;

EID: 84892149143     PISSN: None     EISSN: 14712296     Source Type: Journal    
DOI: 10.1186/1471-2296-15-3     Document Type: Article

References (25)

1. Laux G, Kühlein T, Gutscher A, Szecsenyi J, Versorgungsforschung in der Hausarztpraxis. Ergebnisse aus dem CONTENT-Projekt 2006-2009 Heidelberg: Springer-Verlag 2010
2. Doctor, would you prescribe a pill to help me. ?A national survey of physicians on using medicine for human enhancement. Hotze TD, Shah K, Anderson EE, Wynia MK, Am J Bioeth 2011 11 1 3 13 10.1080/15265161.2011.534957
3. Pharmacological neuroenhancement and brain doping: Chances and risks. Franke AG, Lieb K, Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2010 53 8 853 859 10.1007/s00103-010-1105-0 20700786
4. Lieb K, Hirndoping-Warum wir nicht alles schlucken sollen Artemis & Winkler: Düsseldorf 2010
5. Botox for the brain: enhancement of cognition, mood and pro-social behavior and blunting of unwanted memories. de Jongh R, Bolt I, Schermer M, Olivier B, Neurosci Biobehav Rev 2008 32 4 760 776 10.1016/j.neubiorev.2007.12. 001 18295885
6. Pharmacological Neuroenhancement: Substances and Epidemiology. Franke AG, Lieb K, Cognitive Enhancement-An Interdisciplinary Perspective by Hildt E, Franke AG Heidelberg: Springer Verlag 2013 17 27
7. Schwabe U, Paffrath D, Arzneiverordnungs-Report 2010 Heidelberg: Springer-Verlag 2010
8. Enhancing concentration, mood and memory in healthy individuals: an empirical study of attitudes among general practitioners and the general population. Bergstrom LS, Lynoe N, Scand J Public Health 2008 36 5 532 537 10.1177/1403494807087558 18635734 (Pubitemid 352044557)
9. Physician attitudes towards pharmacological cognitive enhancement: safety concerns are paramount. Banjo OC, Nadler R, Reiner PB, PLoS One 2011 5 12 14322
10. Use of cognitive enhancement medication among northern italian university students. Castaldi S, Gelatti U, Orizio G, Hartung U, Moreno-Londono AM, Nobile M, Schulz PJ, J Addict Med 2012 6 2 112 117 10.1097/ADM.0b013e3182479584 22456492
11. Randomized response estimates for the 12-month prevalence of cognitive-enhancing drug use in university students. Dietz P, Striegel H, Franke AG, Lieb K, Simon P, Ulrich R, Pharmacotherapy 2013 33 1 44 50 10.1002/phar.1166 23307544
12. Non-medical Use of prescription stimulants and illicit Use of stimulants for cognitive enhancement in pupils and students in Germany. Franke AG, Bonertz C, Christmann M, Huss M, Fellgiebel A, Hildt E, Lieb K, Pharmacopsychiatry 2011 44 2 60 66 10.1055/s-0030-1268417 21161883
13. Use of coffee, caffeinated drinks and caffeine tablets for cognitive enhancement in pupils and students in Germany. Franke AG, Christmann M, Bonertz C, Fellgiebel A, Huss M, Lieb K, Pharmacopsychiatry 2011 44 7 331 338 21993866
14. The use of prescription stimulants to enhance academic performance among college students in health care programs. Herman L, Shtayermman O, Aksnes B, Anzalone M, Cormerais A, Liodice C, J Physician Assist Educ 2011 22 4 15 22
15. Prevalence of stimulant use in a sample of US medical students. Webb JR, Valasek MA, North CS, Ann Clin Psychiatry 2013 25 1 27 32 23376867
16. Cognitive-enhancing substance use at German universities: frequency, reasons and gender differences. Mache S, Eickenhorst P, Vitzthum K, Klapp BF, Groneberg DA, Wien Med Wochenschr 2012 162 11-12 262 271 22707077
17. Prevalence and motives for illicit use of prescription stimulants in an undergraduate student sample. Teter CJ, McCabe SE, Cranford JA, Boyd CJ, Guthrie SK, J Am Coll Health 2005 53 6 253 262 10.3200/JACH.53.6.253-262 15900989 (Pubitemid 40720541)
18. Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration. Teter CJ, McCabe SE, LaGrange K, Cranford JA, Boyd CJ, Pharmacotherapy 2006 26 10 1501 1510 10.1592/phco.26.10.1501 16999660 (Pubitemid 44521735)
19. Middendorf E, Poskowsky J, Isserstedt W, Formen der Stresskompensation und Leistungssteigerung bei Studierenden. HISBUS-Befragung zur Verbreitung und zu Mustern von Hirndoping und Medikamentenmissbrauch HIS Hochschul-Informations- System GmbH: Hannover 2012
20. Poll results: look who's doping. Maher B, Nature 2008 452 7188 674 675 10.1038/452674a 18401370 (Pubitemid 351521058)
21. Use of illicit and prescription drugs for cognitive or mood enhancement among surgeons. Franke AG, Bagusat C, Dietz P, Hoffmann I, Simon P, Ulrich R, Lieb K, BMC Med 2013 11 102 10.1186/1741-7015-11-102 23570256
22. What users think about the differences between caffeine and illicit/prescription stimulants for cognitive enhancement. Franke AG, Lieb K, Hildt E, PLoS One 2012 7 6 40047 10.1371/journal.pone.0040047 22768218
23. Determinants of physicians' prescribing behaviour of methylphenidate for cognitive enhancement. Ponnet K, Wouters E, Van Hal G, Heirman W, Walrave M, Psychol Health Med 2013
24. Responding to requests from adult patients for neuroenhancements: guidance of the Ethics Law and Humanities Committee. Larriviere D, Williams MA, Rizzo M, Bonnie RJ, Neurology 2009 73 17 1406 1412 10.1212/WNL.0b013e3181beecfe 19776378
25. Pediatric neuroenhancement: ethical, legal, social, and neurodevelopmental implications. Graf WD, Nagel SK, Epstein LG, Miller G, Nass R, Larriviere D, Neurology 2013 80 13 1251 1260 10.1212/WNL.0b013e318289703b 23486879